Identity
Astrazeneca Farmaceutica Spain, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €75.0M | |
| 2025 | €136.8M | |
| 2024 | €58.3M | |
| + regional platforms | ||
| 2023 | €16.0M | |
| 2022 | €22.1M | |
| 2021 | €20.0M | |
| 2020 | €12.2M | |
| 2019 | €3.5M | |
In figures
Volume
Between 2019 and 2026 it won 492 contracts worth €344M on its own, with 48 buyers. Its 7 joint-venture (UTE) contracts are shown separately.
Price
It has fewer than 3 comparable awards, too few to compute its median discount.
Competition
Since 2024, 0% of its comparable value was won with a discount and against other bidders. It was the only bidder in 96% of its contracts (2019–2026).
Renewals
52 contracts (€28.5M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Astrazeneca Farmaceutica Spain, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Astrazeneca Farmaceutica Spain, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
Only 2 contested awards can be compared — not enough to read how it prices. Of its 492 contracts, 288 are call-offs under framework agreements and 92 were awarded without competition (negotiated without publicity or direct award).
Framework call-offs 288 · Single bidder 18 · Non-competitive procedure 92 · No comparable budget 92 · Contested, comparable 2
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
How it wins
Whether it wins with or without competition.
68% of the comparable value since 2024 (€3.87M of €5.69M) was won at the tender price and without other bidders. €1.81M (32%) was awarded with a discount and without other bidders.
Comparable: 12 awards with a published budget and bidder count (€5.69M of €270M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2019 and 2026, 83.5% of the value was awarded through negotiated without publicity procedure (61.7% of contracts); followed by Open (7.1%) and Based on a framework agreement (4.8%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 52 of its contracts come up for tender again, worth €28.5M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €68.7k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €50.2k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €45.2k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €27.5k |
| 2026 | Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | — |
and 47 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 12 | 65 M | 2024–2026 |
| Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín | 206 | 51 M | 2019–2026 |
| Servicio Andaluz de Salud | 65 | 40 M | 2024–2026 |
| Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | 6 | 32 M | 2022–2026 |
| Servicio Murciano de Salud - Junta de Compras | 21 | 31 M | 2020–2024 |
and 43 more buyers
Between 2019 and 2026, 99.1% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 478 contracts); followed by Chemical products (CPV 24), with 0.9%.
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 07/08/2026 | cpca 2º cbam astrazeneca farmaceutica spain, saam centralizado exp 578/2025 de medicamentos exclusi… | Servicio Andaluz de Salud | 1 | €385k |
| 25/06/2026 | huj_cbam_am 8/2025_astrazeneca farmacéutica spain, s.a_suministro de medicamentos exclusivos xi (re… | Servicio Andaluz de Salud | 1 | €308k |
| 08/06/2026 | cpca 1º cbam astrazeneca farmaceutica spain s.a. am 578/2025 | Servicio Andaluz de Salud | 1 | €1.01M |
| 19/03/2026 | huj_cbam 5_am 8/2025_astrazeneca farmacéutica spain, s.a._ suministro de medicamentos exclusivos xi… | Servicio Andaluz de Salud | 1 | €562k |
| 12/03/2026 | huj_2cbam_am 376/2025_astrazéneca farmacéutica spain, s.a._suministro de medicamentos exclusivos xi… | Servicio Andaluz de Salud | 1 | €144k |